Tocilizumab antibody | AbD22155_hIgG1
A microtiter plate was coated over night with various antigens at a concentration of 5 μg/ml. After washing and blocking with PBST+5% BSA, detection was performed using HRP-conjugated Human anti tocilizumab (clone AbD22155_hIgG1) at a concentration of 2 μg/ml in HISPEC assay diluent (BUF049A) and QuantaBlu™ fluorogenic peroxidase substrate
A microtiter plate was coated over night with tocilizumab, human interleukin-6 receptor (hIL-6R), human IgG1/kappa or human IgG1/lambda at a concentration of 5 μg/ml. After washing and blocking with PBST+5% BSA, the hIL-6R/tocilizumab complex was formed by adding tocilizumab to hIL-6R-coated wells for an incubation period of 1 hour. Detection was subsequently performed using HRP-conjugated Human anti tocilizumab (clone AbD22155_hIgG1) titrated to the given concentrations in PBST, followed by QuantaBlu™ fluorogenic peroxidase substrate. Data is presented as the mean of three measurements
A microtiter plate was coated over night with Human anti tocilizumab (clone AbD21362, HCA252) at a concentration of 1 μg/ml. After washing and blocking with PBST+5% BSA, 10% human serum was added spiked with increasing concentrations of tocilizumab. Detection was performed using HRP-conjugated Human anti tocilizumab (clone AbD22155_hIgG1) at a concentration of 1 μg/ml in HISPEC assay diluent (BUF049A) and QuantaBlu™ fluorogenic peroxidase substrate. Data is presented as the mean of three measurements
A microtiter plate was coated over night with human interleukin 6 receptor at a concentration of 1 μg/ml. After washing and blocking with PBST+5% BSA, a pre-incubated mixture of tocilizumab (0.3 μg/ml) plus increasing concentrations of the monovalent Fab fragment of the non-inhibitory Human anti tocilizumab clone AbD22155_hIgG1 or the inhibitory clone AbD21338_hIgG (HCA253) was added. Free tocilizumab, still capable of binding to the human interleukin 6 receptor-coated plate, was detected using Mouse anti Human IgG (Fc) CH2 Domain:HRP (MCA647P) and QuantaBlu™ fluorogenic peroxidase substrate. Data is presented as the mean of three measurements
Human anti Tocilizumab:HRP
Anti-tocilizumab antibody is a non-neutralizing anti-idiotypic antibody in full IgG1 format, ideal for bioanalytical assays for tocilizumab and biosimilars. It does not inhibit the binding of tocilizumab to IL-6R and therefore is ideal for a PK bridging ELISA with HCA252 to detect total drug.
Human anti Tocilizumab
Anti-tocilizumab antibody is a non-neutralizing anti-idiotypic antibody in full IgG1 format, ideal for bioanalytical assays for tocilizumab and biosimilars. It does not inhibit the binding of tocilizumab to IL-6R and therefore is ideal for a PK bridging ELISA with HCA252 to detect total drug.
- Product Type
- Monoclonal Antibody
- Clone
- AbD22155_hIgG1
- Isotype
- IgG1
| Product Code | Applications | Datasheet | MSDS | Pack Size | List Price | Quantity |
|---|---|---|---|---|---|---|
| HCA257P | E | 0.1 mg | ||||
| HCA257 | E | 0.1 mg |
Human anti tocilizumab, clone AbD22155_hIgG1 is a non-paratope specific, anti-idiotypic antibody that binds to free tocilizumab and also to tocilizumab in bound to its target, human interleukin-6 receptor (IL-6R). The antibody can be used to measure total levels of tocilizumab and biosimilar products in bioanalytical assays.
Clone AbD22155_hIgG1 can be used to develop a pharmacokinetic (PK) bridging assay to measure total drug levels (free drug, partially bound and fully bound). The antibody, HRP-conjugated and in full immunoglobulin (Ig) format, is recommended as the detection antibody, paired with capture antibody clone AbD21362 (HCA252) in monovalent Fab format. The antibody in Ig format can also be used to develop and calibrate immune response assays to measure the anti-drug antibody (ADA) response in patient sera.
Tocilizumab, marketed under the brand name RoActemra® in Europe and Actemra® in North America, is a humanized IgG1/kappa monoclonal antibody approved for the treatment of moderate to severe rheumatoid arthritis and for the treatment of systemic juvenile idiopathic arthritis. The therapeutic antibody, directed against IL-6R, acts by blocking the binding of IL-6R (both the soluble form, sIL-6R, and the membrane bound form, mIL-6R) to IL-6, thus impeding the pro-inflammatory properties of this cytokine.
View a summary of all anti-tocilizumab antibodies
Clone AbD22155_hIgG1 can be used to develop a pharmacokinetic (PK) bridging assay to measure total drug levels (free drug, partially bound and fully bound). The antibody, HRP-conjugated and in full immunoglobulin (Ig) format, is recommended as the detection antibody, paired with capture antibody clone AbD21362 (HCA252) in monovalent Fab format. The antibody in Ig format can also be used to develop and calibrate immune response assays to measure the anti-drug antibody (ADA) response in patient sera.
Tocilizumab, marketed under the brand name RoActemra® in Europe and Actemra® in North America, is a humanized IgG1/kappa monoclonal antibody approved for the treatment of moderate to severe rheumatoid arthritis and for the treatment of systemic juvenile idiopathic arthritis. The therapeutic antibody, directed against IL-6R, acts by blocking the binding of IL-6R (both the soluble form, sIL-6R, and the membrane bound form, mIL-6R) to IL-6, thus impeding the pro-inflammatory properties of this cytokine.
View a summary of all anti-tocilizumab antibodies
Product Details
- Product Form
- Human IgG1 antibody (lambda light chain) selected from the HuCAL® phage display library and expressed in a human cell line. Conjugated to horseradish peroxidase (HRP) - liquid.
- Product Form
- Human IgG1 antibody (lambda light chain) selected from the HuCAL® phage display library and expressed in a human cell line. This antibody is supplied as a liquid.
- Preparation
- Purified IgG prepared by affinity chromatography on Protein A
- Preparation
- Purified IgG prepared by affinity chromatography on Protein A
- Buffer Solution
- Phosphate buffered saline
- Buffer Solution
- Phosphate buffered saline
- Preservative Stabilisers
- 0.01% Thiomersal
- Preservative Stabilisers
- 0.01% Thiomersal
- Immunogen
- Tocilizumab and tocilizumab-sIL-6R complex
- Affinity
- The monovalent intrinsic affinity of this antibody was measured as KD = 31 nM by real time, label free molecular interaction analysis on immobilized tocilizumab.
- Approx. Protein Concentrations
- IgG concentration 0.1 mg/ml
- Approx. Protein Concentrations
- IgG concentration 0.5 mg/ml
Storage Information
- Storage
- Store at -70oC.
Storage in frost-free freezers is not recommended.
This product should be stored undiluted. Avoid repeated freezing and thawing as this may denature the antibody. - Storage
- Store at +4oC or at -20oC if preferred.
Storage in frost-free freezers is not recommended.
This product should be stored undiluted. Avoid repeated freezing and thawing as this may denature the antibody. Should this product contain a precipitate we recommend microcentrifugation before use - Guarantee
- 12 months from date of despatch
- Guarantee
- 12 months from date of despatch
More Information
- Acknowledgements
- Sold under license of U.S. Patents 6753136, 7785859 and 8273688 and corresponding patents. This antibody was developed by Bio-Rad, Zeppelinstr. 4, 82178 Puchheim, Germany.
Actemra® and RoActemra® are registered trademarks of Hoffman-La Roche and Chugai Pharmaceuticals co., Ltd. - Acknowledgements
- Sold under license of U.S. Patents 6753136, 7785859 and 8273688 and corresponding patents. This antibody was developed by Bio-Rad, Zeppelinstr. 4, 82178 Puchheim, Germany.
Actemra® and RoActemra® are registered trademarks of Hoffman-La Roche and Chugai Pharmaceuticals co., Ltd. - Licensed Use
- For in vitro research purposes and for commercial applications for the provision of in vitro testing services to support preclinical and clinical drug development. Any re-sale in any form or any other commercial application needs a written agreement with Bio-Rad.
- Regulatory
- For research purposes only
Applications of Tocilizumab antibody
| Application Name | Verified | Min Dilution | Max Dilution |
|---|---|---|---|
| ELISA | |||
| ELISA |
Where this product has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the product for use in their own system using appropriate negative/positive controls.
Where this product has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the product for use in their own system using appropriate negative/positive controls.
- Technical Advice
- Recommended protocols and further information about HuCAL recombinant antibody technology can be found in the HuCAL Antibodies Technical Manual
- Technical Advice
- Recommended protocols and further information about HuCAL recombinant antibody technology can be found in the HuCAL Antibodies Technical Manual
- ELISA
- This product may be used in a direct ELISA or as a detection reagent in a bridging ELISA together with HCA252 as the capture reagent.
Protocol: PK bridging ELISA to measure total drug - ELISA
- This product may be used in a direct ELISA or as a detection reagent in a bridging ELISA together with HCA252 as the capture reagent.
Protocol: PK bridging ELISA to measure total drug
Copyright © 2019 Bio-Rad Antibodies (formerly AbD Serotec)
Useful Reagents Available
| Description | Product Code | Pack Size | Applications | List Price | Quantity |
|---|---|---|---|---|---|
| Hispec Assay Diluent | BUF049A | 50 ml | E IY | ||
| Human anti Tocilizumab | HCA252 | 0.1 mg | E* | ||
| Human anti Tocilizumab | HCA253 | 0.1 mg | E | ||
| Human anti Tocilizumab | HCA254 | 0.1 mg | E | ||
| Human anti Tocilizumab | HCA255 | 0.1 mg | E | ||
| Human anti Tocilizumab | HCA256 | 0.1 mg | E | ||
| Hispec Assay Diluent | BUF049A | 50 ml | E IY | ||
| Human anti Tocilizumab | HCA252 | 0.1 mg | E* | ||
| Human anti Tocilizumab | HCA253 | 0.1 mg | E | ||
| Human anti Tocilizumab | HCA254 | 0.1 mg | E | ||
| Human anti Tocilizumab | HCA255 | 0.1 mg | E | ||
| Human anti Tocilizumab | HCA256 | 0.1 mg | E | ||
| LYNX Rapid HRP Antibody Conjugation Kit | LNK001P | 1 Conjugation For 400µg Antibody | CJ | ||
| LYNX Rapid HRP Antibody Conjugation Kit | LNK002P | 3 Conjugations For 400µg Antibody | CJ | ||
| LYNX Rapid HRP Antibody Conjugation Kit | LNK003P | 1 Conjugation For 4mg Antibody | CJ | ||
| LYNX Rapid HRP Antibody Conjugation Kit | LNK004P | 5 Conjugations For 4mg Antibody | CJ | ||
| LYNX Rapid HRP Antibody Conjugation Kit | LNK005P | 1 Conjugation For 20mg Antibody | CJ | ||
| LYNX Rapid HRP Antibody Conjugation Kit | LNK006P | 3 Conjugations For 40µg Antibody | CJ |
Product Specific References
References for Tocilizumab antibody
-
Kashiwagi, N. et al. (2017) Method for measuring anti-drug antibody
US Patent Application US20170315118A1
